Cyclo Therapeutics (Cyclo Therapeutics) Debt-to-EBITDA : -0.05 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Cyclo Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cyclo Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.01 Mil. Cyclo Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.02 Mil. Cyclo Therapeutics's annualized EBITDA for the quarter that ended in Dec. 2023 was $-22.55 Mil. Cyclo Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cyclo Therapeutics's Debt-to-EBITDA or its related term are showing as below:

CYTH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.95 Med: -0.04 Max: -0.01
Current: -0.05

During the past 13 years, the highest Debt-to-EBITDA Ratio of Cyclo Therapeutics was -0.01. The lowest was -1.95. And the median was -0.04.

CYTH's Debt-to-EBITDA is ranked worse than
100% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs CYTH: -0.05

Cyclo Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Cyclo Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclo Therapeutics Debt-to-EBITDA Chart

Cyclo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.01

-0.02

-0.01

-0.05

Cyclo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-	-	-	-	-0.05

Competitive Comparison of Cyclo Therapeutics's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Cyclo Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclo Therapeutics's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyclo Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cyclo Therapeutics's Debt-to-EBITDA falls into.

Cyclo Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cyclo Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.011	+	0.022)	/	-20.031
	=	-0.05

Cyclo Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.011	+	0.022)	/	-22.552
	=	-0.05

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Cyclo Therapeutics (NAS:CYTH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Cyclo Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclo Therapeutics (Cyclo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTH) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653

Website

https://www.cyclodex.com

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.

Executives

Vivien Wong	director	6C CHATEAUX CIRCLE, SCARSDALE NY 10583
Rafael Holdings, Inc.	10 percent owner	520 BROAD STREET, NEWARK NJ 07120
William Conkling	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Jeffrey Tate	director, officer: Chief Executive Officer	C/O CTD HOLDINGS, INC., 27317 NW 78TH AVENUE, HIGH SPRINGS FL 32643
Francis Patrick Ostronic	director	932 HUNGERFORD DRIVE, SUITE 28A, ROCKVILLE MD 20850
Markus Sieger	director	BEUTSTWEG 12, CH-8032, ZURICH V8 000000000
N Scott Fine	director	600 3RD AVE, NEW YORK NY 10016
Sharon Hemond Hrynkow	officer: SVP for Medical Affairs	4816 KING SOLOMON DRIVE, ANNADALE VA 22003
Lise Lund Kjems	officer: Chief Medical Officer	91 ROLLINGWOOD LN., CONCORD MA 01742
Joshua M Fine	officer: Chief Financial Officer	21 HEMMELSKAMP ROAD, WILTON CT 06897
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Michael Eric Lisjak	officer: Chief Regulatory Officer	12 ROOSEVELT AVENUE, OLD GREENWICH CT 06870
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
L.p. Novit,	10 percent owner	966 HUNGERFORD DRIVE, ROCKVILLE MD 20850